Investor Relations
Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Investor Relations
Focused on enhancing shareholder value through creating and delivering meaningful advancements in early intervention orthopedic care.
Stock quote is delayed by 15 minutes
NASDAQANIK
Financial and Operational Metrics
(As of June 30, 2024)
-
$167M
TTM Revenue
-
$25-30M*
Adj. EBITDA expected in 2024
~15%
Adj. EBITDA
Margin -
$63M
Cash balance
with no debt
-
#1
OA Pain
U.S. Market Share
~25M
Injections
Worldwide
*Anticipate towards the lower end of range
Current Investor Presentation
Latest Quarterly Results
Q2 2024 Earnings
Investor Contacts
Primary IR Contact
-
Matt Hall
Director, Corporate Development and Investor Relations
Anika Therapeutics, Inc.
Phone: (781) 457-9554
Email: investorrelations@anika.com
-
Transfer Agent
Equiniti Trust Company LLC
6201 15th Avenue
Brooklyn NY 11219
Phone: (800) 937-5449
Want Alerts? Sign up for alerts and never miss an Investor update!